Renal transplantation in amyloidosis: effects of HLA matching and donor type on recurrence of primary disease.
The aim of this study is to evaluate the effect of HLA-matching and donor type on recurrence of amyloidosis after renal transplantation. The study includes 30 patients with systemic amyloidosis who received kidney transplants between 1985 and 2001. Donor source and HLA tissue typing of the donor and recipient were evaluated in each case. Of the 30 patients, 20 developed a recurrence of amyloidosis in their allografts, as confirmed by biopsy. The time from transplantation to diagnosis of amyloidosis in the graft ranged from 18 months to 10 years. Of the 20 patients with recurrence, 18 had received their grafts from living related donors (LRDs), and 2 had received their grafts from cadaveric donors (P < 0.01). There was a strong correlation between amyloidosis recurrence and degree of HLA-DR matching (P < 0.05). Furthermore, in the recipients of LRD grafts, the risk of amyloidosis recurrence was much higher if the donor-recipient pair were HLA-identical than if they were not perfectly matched (P < 0.01). The incidence of amyloidosis recurrence in our patients was significantly higher than the rates reported for other series. Most of the cases in previous reports involved cadaveric grafts. The higher rate of amyloidosis recurrence in our patients may be explained by the high proportion of LRD grafts and by genetic susceptibility.
Ozdemir
Binnaz Handan
BH
GOP Ankara, Bağlar caddesi 194-6, 06700 Ankara, Turkey. handan27@hotmail.com
Ozdemir
Fatma Nurhan
FN
Demirhan
Beyhan
B
Turan
Münire
M
Haberal
Mehmet
M
D000328:Adult; D000686:Amyloidosis / Q000209:etiology / Q000601:surgery*; D005260:Female; D006650:Histocompatibility Testing; D006801:Humans; D007674:Kidney Diseases / Q000601:surgery*; D016030:Kidney Transplantation / Q000276:immunology* / Q000502:physiology; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology; D012008:Recurrence; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome